Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
developing an hl7 fhir implementation guide for rare cancers the idea4rc project experience
Original title: “Developing an HL7 FHIR Implementation Guide for Rare Cancers: The IDEA4RC Project Experience.”
The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that AVLAYAH (tividenofusp alfa-eknm), approve
Original title: “Issuance of Priority Review Voucher; Rare Pediatric Disease Product; AVLAYAH (tividenofusp alfa-eknm)”
diagnostic utility of clinical genome reanalysis in rare pediatric disorders using long read sequencing
Original title: “Diagnostic utility of clinical genome reanalysis in rare pediatric disorders using long-read sequencing.”
diagnostic yield and genetic landscape of rare pediatric diseases in vietnam identified by exome sequencing
Original title: “Diagnostic yield and genetic landscape of rare pediatric diseases in Vietnam identified by exome sequencing.”
boosting pathology foundation models via few shot prompt tuning for rare cancer subtyping
Original title: “Boosting pathology foundation models via few-shot prompt-tuning for rare cancer subtyping.”
Rhythm said that the failed trial of Imcrivee suffered a high dropout rate, which impacted the primary endpoints. No new safety signals were observed with Imcrivee, and the safety profile was consistent with prior clinical studies and commercial experience. The most common treatment-emergent adverse events (TEAEs) included skin hyperpigmentation, injection site reactions, nausea, vomiting, and headache. There had been a very high drop out rate in the trial, the company confirmed during an investor call. As a result, when using post hoc analysis using last observation carried forward for missing values, Imcrivee achieved statistically significant and clinically meaningful BMI reductions in the modified intent-to-treat patient populations in the POMC/PCSK1 Hets (5.5%) and SRC1 (6.2%). Dr David Meeker, CEO of Rhythm Pharmaceuticals, said: “While we are disappointed the EMANATE substudies did not meet their primary endpoint, we are encouraged by compelling signals from additional analyses of the heterozygous POMC/PCSK1 and SRC1 substudies and learnings that sharpen our ability to identify true loss-of-function variants and inform the development of our next-generation MC4R agonists in rare genetically driven obesity indications.” ... Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strat A Phase III trial of Rhythm Pharmaceuticals’ Imcivree (setmelanotide) failed to meet its primary endpoints in four rare, genetically driven obesities of the MC4R pathway.
Original title: “Rhythm’s Imcivree fails Phase III rare disease obesity trial - Clinical Trials Arena”